Overview Dividends

(CGON) CG Oncology, Common stock - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1569441009

Oncolytic Immunotherapy, Cretostimogene, BCG-Unresponsive NMIBC, Muscle-Invasive Bladder Cancer

EPS (Earnings per Share)

EPS (Earnings per Share) of CGON over the last years for every Quarter: "2021-12": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": -0.3309, "2024-03": -0.36, "2024-06": -0.28, "2024-09": -0.3, "2024-12": -0.46, "2025-03": -0.45, "2025-06": -0.54, "2025-09": -0.57,
EPS Growth (3y CAGR): -66.85%
EPS Trend (3y Corr): -85.9%
Last SUE: -3.62σ
Qual. Beats: 0

Revenue

Revenue of CGON over the last years for every Quarter: 2021-12: null, 2022-12: 0, 2023-03: 0.194, 2023-06: 0, 2023-09: 0.009, 2023-12: 0.001, 2024-03: 0.529, 2024-06: 0.111, 2024-09: 0.043, 2024-12: 0.456, 2025-03: 0.052, 2025-06: 0, 2025-09: null,
Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): 15.4%
Last SUE: -1.26σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 66.5%
Value at Risk 5%th 101%
Relative Tail Risk -7.42%
Reward TTM
Sharpe Ratio 0.60
Alpha 6.25
Character TTM
Hurst Exponent 0.333
Beta 1.499
Beta Downside 1.447
Drawdowns 3y
Max DD 67.47%
Mean DD 31.13%
Median DD 30.67%

Description: CGON CG Oncology, Common stock November 11, 2025

CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharma focused on bladder-sparing immunotherapies for bladder cancer, a market valued at roughly $5 billion in the United States with limited treatment options for BCG-unresponsive non-muscle invasive disease.

The company’s pipeline includes:

  • BOND-003 – a phase 3 trial targeting high-risk BCG-unresponsive NMIBC.
  • CORE-001 – phase 2 evaluating cretostimogene plus pembrolizumab in the same patient cohort.
  • CORE-002 – phase 2 testing cretostimogene with nivolumab for muscle-invasive bladder cancer.
  • PIVOT-006 – a cretostimogene monotherapy in phase 3 for intermediate-risk NMIBC after TURBT, developed under a collaboration with Merck.
  • CORE-008 – phase 2 for high-risk NMIBC, enrolling both BCG-exposed and BCG-naïve patients.

Founded in 2010 (originally Cold Genesys) and headquartered in Irvine, California, CG Oncology rebranded in June 2020. As of the latest quarterly filing, the firm reported approximately $70 million of cash and marketable securities, providing a runway into 2025, while the broader biotech sector benefits from sustained R&D tax credits and FDA’s accelerated-approval pathways for immuno-oncology assets.

For a deeper quantitative assessment of CGON’s risk-adjusted upside, you may find the ValueRay platform’s forward-looking valuation model useful.

CGON Stock Overview

Market Cap in USD 2,879m
Sub-Industry Biotechnology
IPO / Inception 2024-01-25
Return 12m vs S&P 500 12.9%
Analyst Rating 4.40 of 5

CGON Dividends

Currently no dividends paid

CGON Growth Ratios

Metric Value
CAGR 3y 5.13%
CAGR/Max DD Calmar Ratio 0.08
CAGR/Mean DD Pain Ratio 0.16
Current Volume 575.6k
Average Volume 806.4k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-128.1m TTM) > 0 and > 6% of Revenue (6% = 33.1k TTM)
FCFTA -0.13 (>2.0%) and ΔFCFTA -1.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 116.6k% (prev 84.9k%; Δ 31.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.13 (>3.0%) and CFO -93.8m > Net Income -128.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 22.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (76.2m) change vs 12m ago 14.37% (target <= -2.0% for YES)
Gross Margin 71.69% (prev -12.6k%; Δ 12.6kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.09% (prev 0.12%; Δ -0.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -5.55 (EBITDA TTM -157.2m / Interest Expense TTM 19.6m) >= 6 (WARN >= 3)

Altman Z'' -6.43

(A) 0.92 = (Total Current Assets 673.0m - Total Current Liabilities 30.4m) / Total Assets 701.4m
(B) -0.42 = Retained Earnings (Balance) -293.9m / Total Assets 701.4m
(C) -0.17 = EBIT TTM -108.5m / Avg Total Assets 632.9m
(D) -9.45 = Book Value of Equity -293.9m / Total Liabilities 31.1m
Total Rating: -6.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.74

1. Piotroski 1.0pt
2. FCF Yield -4.24%
3. FCF Margin data missing
4. Debt/Equity 0.00
5. Debt/Ebitda 0.09
6. ROIC - WACC (= -24.50)%
7. RoE -19.37%
8. Rev. Trend 15.38%
9. EPS Trend -85.86%

What is the price of CGON shares?

As of November 21, 2025, the stock is trading at USD 40.71 with a total of 575,556 shares traded.
Over the past week, the price has changed by +7.81%, over one month by -6.61%, over three months by +59.46% and over the past year by +26.27%.

Is CGON a buy, sell or hold?

CG Oncology, Common stock has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy CGON.
  • Strong Buy: 5
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CGON price?

Issuer Target Up/Down from current
Wallstreet Target Price 68.1 67.2%
Analysts Target Price 68.1 67.2%
ValueRay Target Price 45.8 12.4%

CGON Fundamental Data Overview November 15, 2025

Market Cap USD = 2.88b (2.88b USD * 1.0 USD.USD)
P/S = 5225.2427
P/B = 4.4848
Beta = None
Revenue TTM = 551.0k USD
EBIT TTM = -108.5m USD
EBITDA TTM = -157.2m USD
Long Term Debt = 994.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 288.0k USD (from shortTermDebt, last quarter)
Debt = 994.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.22b USD (2.88b + Debt 994.0k - CCE 661.1m)
Interest Coverage Ratio = -5.55 (Ebit TTM -108.5m / Interest Expense TTM 19.6m)
FCF Yield = -4.24% (FCF TTM -94.1m / Enterprise Value 2.22b)
FCF Margin = -17.1k% (FCF TTM -94.1m / Revenue TTM 551.0k)
Net Margin = -23.2k% (Net Income TTM -128.1m / Revenue TTM 551.0k)
Gross Margin = 71.69% ((Revenue TTM 551.0k - Cost of Revenue TTM 156.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev 100.0%)
Tobins Q-Ratio = 3.16 (Enterprise Value 2.22b / Total Assets 701.4m)
Interest Expense / Debt = 1968 % (Interest Expense 19.6m / Debt 994.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -85.7m (EBIT -108.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.15 (Total Current Assets 673.0m / Total Current Liabilities 30.4m)
Debt / Equity = 0.00 (Debt 994.0k / totalStockholderEquity, last quarter 670.4m)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -13.6m / EBITDA -157.2m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -13.6m / FCF TTM -94.1m)
Total Stockholder Equity = 661.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.26% (Net Income -128.1m / Total Assets 701.4m)
RoE = -19.37% (Net Income TTM -128.1m / Total Stockholder Equity 661.3m)
RoCE = -16.38% (EBIT -108.5m / Capital Employed (Equity 661.3m + L.T.Debt 994.0k))
RoIC = -12.96% (negative operating profit) (NOPAT -85.7m / Invested Capital 661.3m)
WACC = 11.54% (E(2.88b)/V(2.88b) * Re(11.54%) + (debt cost/tax rate unavailable))
Discount Rate = 11.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 6.95%
Fair Price DCF = unknown (Cash Flow -94.1m)
EPS Correlation: -85.86 | EPS CAGR: -66.85% | SUE: -3.62 | # QB: 0
Revenue Correlation: 15.38 | Revenue CAGR: 0.0% | SUE: -1.26 | # QB: 0

Additional Sources for CGON Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle